Emerging imaging targets for infiltrative cardiomyopathy: Inflammation and fibrosis
- PMID: 29968156
- DOI: 10.1007/s12350-018-1356-y
Emerging imaging targets for infiltrative cardiomyopathy: Inflammation and fibrosis
Abstract
Molecular imaging in infiltrative cardiomyopathies is increasingly penetrating the clinical arena. Current approaches target the infiltrate directly, or its metabolic, physiologic, or functional consequences. Inflammation may not just play a role as the infiltrative mechanism itself. It is also thought to play a key role in the development and progression of heart failure in general, because it promotes the development of tissue fibrosis. The cascade leading from tissue damage to inflammation and further to fibrosis and loss of function has emerged as a therapeutic target. This review focuses (1) on novel tracers of inflammation, which are on the brink of clinical applicability and may be more specific than the gross metabolic marker F-18 deoxyglucose; and (2) on novel biologic imaging targets in fibrosis, which may be exploited for interrogation of the crosstalk between inflammation and loss of contractile function. Ultimately, the success of any novel molecular imaging assay will depend on whether it can be used for successful guidance of novel, targeted therapies aiming at tissue regeneration.
Keywords: Molecular imaging; fibrosis; infiltrative cardiomyopathy; inflammation.
Similar articles
-
Molecular phenotyping of infiltrative cardiomyopathies: The future.J Nucl Cardiol. 2019 Feb;26(1):154-157. doi: 10.1007/s12350-018-01550-6. Epub 2018 Dec 10. J Nucl Cardiol. 2019. PMID: 30535918
-
State-of-the-Art Imaging of Infiltrative Cardiomyopathies: A Scientific Statement From the American Heart Association.Circ Cardiovasc Imaging. 2023 Nov;16(11):e000081. doi: 10.1161/HCI.0000000000000081. Epub 2023 Nov 2. Circ Cardiovasc Imaging. 2023. PMID: 37916407 Review.
-
Advanced cardiovascular imaging for the evaluation of cardiac sarcoidosis.J Nucl Cardiol. 2019 Feb;26(1):188-199. doi: 10.1007/s12350-018-01488-9. Epub 2018 Nov 2. J Nucl Cardiol. 2019. PMID: 30390241 Free PMC article. Review.
-
Clinical evaluation of infiltrative cardiomyopathies resulting in heart failure with preserved ejection fraction.Rev Cardiovasc Med. 2020 Jun 30;21(2):181-190. doi: 10.31083/j.rcm.2020.02.65. Rev Cardiovasc Med. 2020. PMID: 32706207 Review.
-
Employing Extracellular Volume Cardiovascular Magnetic Resonance Measures of Myocardial Fibrosis to Foster Novel Therapeutics.Circ Cardiovasc Imaging. 2017 Jun;10(6):e005619. doi: 10.1161/CIRCIMAGING.116.005619. Circ Cardiovasc Imaging. 2017. PMID: 28512159 Review.
Cited by
-
PET Imaging in Cardiac Sarcoidosis: A Narrative Review with Focus on Novel PET Tracers.Pharmaceuticals (Basel). 2021 Dec 9;14(12):1286. doi: 10.3390/ph14121286. Pharmaceuticals (Basel). 2021. PMID: 34959686 Free PMC article. Review.
-
Novel Radiotracers for Molecular Imaging of Myocardial Inflammation: an Update Focused on Clinical Translation of Non-18F-FDG Radiotracers.Curr Cardiovasc Imaging Rep. 2023;16(1):1-9. doi: 10.1007/s12410-023-09574-4. Epub 2023 Mar 9. Curr Cardiovasc Imaging Rep. 2023. PMID: 36926261 Free PMC article. Review.
-
Roles of MDA-LDL/OX-LDL/LOX-1 and TNF-α/TLR4/NF-κB Signaling Pathways in Myocardial Damage by Implantations of Cardiac Pacemakers in Elderly Patients.Curr Vasc Pharmacol. 2024;22(4):251-265. doi: 10.2174/0115701611260215231221072709. Curr Vasc Pharmacol. 2024. PMID: 38920075
-
PET Tracers for Imaging Cardiac Function in Cardio-oncology.Curr Cardiol Rep. 2022 Mar;24(3):247-260. doi: 10.1007/s11886-022-01641-4. Epub 2022 Jan 13. Curr Cardiol Rep. 2022. PMID: 35028820 Free PMC article. Review.
-
Optimized New Shengmai Powder modulation of cAMP/Rap1A signaling pathway attenuates myocardial fibrosis in heart failure.Chin Med. 2024 Feb 24;19(1):30. doi: 10.1186/s13020-024-00902-4. Chin Med. 2024. PMID: 38402401 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical